HUTCHMED Completes Enrollment of Phase II Gastric Cancer Study
Why we think this is neutral
The RNS announcement provides an update on the completion of patient enrollment for a Phase II study of savolitinib in gastric cancer. While this is a positive development, the announcement does not contain any of the mandatory news types that would warrant a stronger sentiment score.
Key Points
- HUTCHMED has completed enrollment of a Phase II registration study of savolitinib in gastric cancer patients with MET amplification
- Interim results showed a 45% objective response rate confirmed by independent review
- HUTCHMED may apply for marketing authorization of savolitinib for gastric cancer in China in late 2025 if the study is positive
Summary
HUTCHMED (China) Limited has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification. The trial is evaluating the efficacy, safety and tolerability of savolitinib in this patient population. Interim results showed a 45% objective response rate confirmed by independent review. The company may apply for marketing authorization of savolitinib for gastric cancer in China in late 2025 if the study is positive.